Martin Shkreli takes over as CEO of KaloBios as stake in the company grows to 70%
Following swiftly on yesterday’s news, KaloBios Pharmaceuticals (Nasdaq: KBIO) announced that an investor group led by Martin Shkreli, the founder and chief executive of privately-held Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares, up from 55% previously.
KaloBios also announced the appointment of Mr Shkreli to the position of chief executive and his election as chairman of the board. In his new role, Mr. Shkreli will work with the company's senior management team to ensure the company's continued operations. KaloBios further announced that David Moradi, Tony Chase and Marek Biestek have been elected to the board of directors. In connection with 0 developments, the former directors have resigned, effective immediately.
Investment commitment
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze